FINWIRES · TerminalLIVE
FINWIRES

$UTHR

84 stories mentioning UTHRUpdated 2d ago

Every FINWIRES story that references UTHR, newest first.

What are analysts saying about UTHR?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on UTHR?

Insider Trading

United Therapeutics Insider Sold Shares Worth $5,201,110, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on June 08, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,201,110. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000072/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,114,742, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on June 02, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,114,742. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000068/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,261,365, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 29, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,261,365. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000065/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,466,283, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 27, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,466,283. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000063/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,729,359, According to a Recent SEC Filing

James Edgemond, CFO and Treasurer, on May 26, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,729,359. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000021/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,393,558, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 22, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,393,558. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000060/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,641,130, According to a Recent SEC Filing

James Edgemond, CFO and Treasurer, on May 21, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,641,130. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000020/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,359,011, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 21, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,359,011. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000059/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,671,399, According to a Recent SEC Filing

Paul A Mahon, Executive Vice President & General Counsel, on May 21, 2026, sold 8,300 shares in United Therapeutics (UTHR) for $4,671,399. Following the Form 4 filing with the SEC, Mahon has control over a total of 45,172 common shares of the company, with 45,172 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000123158926000012/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,376,814, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 20, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,376,814. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000058/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,395,399, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 19, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,395,399. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000057/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,397,077, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & Chief Executive Officer, on May 15, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,397,077. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000055/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,744,746, According to a Recent SEC Filing

James Edgemond, CFO and Treasurer, on May 14, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,744,746. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000018/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,497,166, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 13, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,497,166. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000053/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,785,775, According to a Recent SEC Filing

James Edgemond, Chief Financial Officer and Treasurer, on May 07, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,785,775. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000016/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,496,084, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson and Chief Executive Officer, on May 07, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,496,084. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000049/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,600,468, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on May 06, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,600,468. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000048/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,870,054, According to a Recent SEC Filing

Paul A Mahon, Executive Vice President & General Counsel, on May 07, 2026, sold 8,300 shares in United Therapeutics (UTHR) for $4,870,054. Following the Form 4 filing with the SEC, Mahon has control over a total of 45,172 common shares of the company, with 45,172 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000123158926000011/xslF345X05/primarydocument.xml

$UTHR
Wire

United Therapeutics Growth Outlook Remains Supported by Tyvaso, Ralinepag, RBC Says

United Therapeutics (UTHR) still has a stronger long-term growth path despite a soft Q1, helped by Tyvaso durability, possible idiopathic pulmonary fibrosis expansion, TreSMI filing plans, and future upside from ralinepag, RBC Capital Markets said in a note emailed Thursday.The investment firm said Tyvaso revenue missed estimates in Q1, but the firm expects the franchise to return to growth after weather issues and specialty pharmacy delays subside.IPF could become the company's next major growth driver, with a supplemental application still planned for this summer and other faster approval paths under review, RBC said.TreSMI remains on track for a US Food and Drug Administration filing in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease by year's end, which could help United Therapeutics defend its position in inhaled treprostinil, according to the note.Ralinepag Dry Powder Inhalation could add longer-term upside because once daily dosing may help the company compete better in pulmonary hypertension and related lung disease markets, RBC added.RBC lowered its price target for United Therapeutics to $701 from $707 while keeping its outperform rating.Price: $576.22, Change: $-20.55, Percent Change: -3.44%

$UTHR
Wire

RBC Capital Adjusts United Therapeutics Price Target to $701 From $707, Maintains Outperform Rating

United Therapeutics (UTHR) has an average rating of buy and mean price target of $670.67, according to analysts polled by FactSet.Price: $585.63, Change: $-11.14, Percent Change: -1.87%

$UTHR

Showing 41-60 of 84

Track with the FINWIRES app suite

FolioX
FolioX
Track UTHR in your portfolio
WheelAI
WheelAI
Analyze UTHR options with the wheel strategy
StockInsider
StockInsider
See market sentiment on UTHR